News
The pharmaceutical firm Novo Nordisk is pursuing a multi-pronged strategy to regain market share that it has lost to Eli ...
Approximately 9,000 CVS locations will begin selling Wegovy for $499 per month to customers who pay cash out of pocket.
CVS’s stock surges toward a one-year high after profit and revenue beat expectations, amid strength in the pharmacy business, ...
Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...
Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...
Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback